U.S. Food and Drug Administration and Department of Health and Human Services Awards Contract to Marshfield Clinic Research Foun
Tuesday, December 8th, 2015 -- 8:15 AM
-Marshfield Clinic Research Foundation has been awarded a contract, including future options valued at $3.1 million, through the U.S. Food and Drug Administration and Department of Health and Human Services to study the effects of generic drugs in the marketplace."Our primary goal is to detect generic-specific or generic-enhanced drug adverse events early so problem drugs can be evaluated and removed from the marketplace earlier, ultimately, to save lives," said Dr. Peggy Peissig, principal investigator of the study and director, Biomedical Informatics Research Center, MCRF.
Peissig will lead a team of study researchers that includes Dr. Michael Caldwell and Richard Berg, MCRF; Dr. David Page, University of Wisconsin-Madison; and Drs. Rick Hansen and Brent Fox, Auburn University. They will develop a surveillance system for early detection of adverse drug events for generic products. The team will use state-of-the-art data mining approaches to detect differences in outcomes between brand and generic drugs and predict patients at risk of experiencing a generic drug adverse outcome.
Feel free to contact us with questions and/or comments.